The Asia-Pacific region is expected to witness the fastest growth in the chemotherapy-induced peripheral neuropathy market. Rising healthcare investments, improving cancer treatment infrastructure, and increasing awareness about neuropathy management are contributing to regional market expansion. The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is gaining significant...